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Aims Proteasome inhibitors are a novel class of anticancer agents that induce tumour cell death via
endoplasmic reticulum (ER) stress. Since ER stress is involved in the development of heart failure, we
investigated the role of ER-initiated cardiomyocyte death by proteasome inhibition.
Methods and results Rat neonatal cardiomyocytes were used in this study. Proteasome activity was
assayed using proteasome peptidase substrates. Cell viability and apoptosis were measured by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenol tetrazolium bromide and ﬂow cytometry, respectively. Western
blot analysis, real-time polymerase chain reaction (PCR) and reverse transcriptional PCR were used
to detect the expression of protein and messenger ribonucleic acid (RNA). The location of overexpressed
glucose-regulated protein (GRP) 78 was observed by confocal ﬂuorescence microscopy. Proteasome
inhibition induced cardiomyocyte death and activated ER stress-induced transcriptional factor ATF6,
but not XBP1 (X-box binding protein 1), without up-regulating ER chaperones. ER-initiated apoptosis sig-
nalling, including cytosine-cytosine-adenine-adenine-thymine enhancer-binding protein (C/EBP) homolo-
gous protein (CHOP), c-Jun-N-terminal kinase (JNK), and caspase-12, was activated by proteasome
inhibition. Short interference RNA targeting CHOP, but not the blockage of caspase-12 or JNK pathway,
attenuated cardiomyocyte death. Overexpression of GRP78 suppressed both CHOP expression and cardio-
myocyte death by proteasome inhibition.
Conclusion These ﬁndings demonstrate that proteasome inhibition induces ER-initiated cardiomyocyte
death via CHOP-dependent pathways without compensatory up-regulation of ER chaperones. Sup-
plement and/or pharmacological induction of GRP78 can attenuate cardiac damage by proteasome
inhibition.
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1. Introduction
Endoplasmic reticulum (ER) is an organelle that participates
in the folding of membrane and secretory proteins. The con-
ditions or stresses that interfere with ER function are named
ER stress.
1 There are two ER stress-induced transcriptional
factors to up-regulate ER-resident chaperones that
promote the folding of accumulated proteins in ER: activat-
ing transcription factor 6 (ATF6) and X-box binding protein 1
(XBP1). ATF6 is cleaved in response to ER stress and the
cleaved ATF6 trafﬁcs to nuclei to induce the expression of
ER-resident chaperone.
2 In addition, ER stress induces
XBP1 messenger ribonucleic acid (mRNA) splicing, producing
a new spliced XBP1 mRNA.
3 The spliced XBP1 protein and
cleaved ATF6 cooperatively up-regulate the expression of
ER-resident chaperones that reduce ER stress.
4 Another
important pathway to cope with ER stress is the degradation
of misfolded proteins by the ubiquitin-proteasome system.
5
It is therefore conceivable that treatment of cells with pro-
teasome inhibitors causes accumulation of misfolded
proteins and ER stress. When the overload of misfolded pro-
teins is not resolved, cell apoptosis signals are initiated from
ER. This effect is mediated by increased expression of
the transcription factor cytosine-cytosine-adenine-adenine-
thymine enhancer-binding protein (C/EBP) homologous
protein (CHOP) and activation of caspase-12 and c-Jun-
N-terminal kinase (JNK).
6–8
Recently, the ubiquitin-proteasome system is reported to
be involved in the growth and survival of cells and
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 considered as an attractive therapeutic target.
9 Proteasome
inhibitors are usually short peptides linked to a pharmaco-
phore that reacts with the active site of proteasome.
10
Based on the pharmacophores, proteasome inhibitors can be
divided into several groups: peptide aldehydes (e.g. MG132),
peptide boronates (e.g. PS341), and peptide epooxyketones
(e.g. epoxomicin).
11 Among these proteasome inhibitors,
bortezomib (PS341) has been used as anticancer agent
against haematological malignancy and solid tumours.
12
Recently, the treatment with bortezomib was reported to be
associated with cardiac failure in patients with lung cancer
and multiple myeloma.
13,14 Furthermore, we have found
that the accumulation of ubiquitinated proteins in failing
heart samples from humans demonstrated the impairment of
proteasome function in failing hearts.
15 These ﬁndings led us
to hypothesize that the proteasome inhibition could cause
cardiomyocyte death via an ER-dependent pathway. To test
this hypothesis, we checked the role of ER-initiated apoptotic
signalling in cardiomyocyte death when proteasome activity
was pharmacologically inhibited. Furthermore, we also inves-
tigated whether overexpression of ER-resident chaperone
could rescue cardiac cell death by proteasome inhibition.
In the present study, we used MG132 and epoxomicin, two
typical proteasome inhibitors, to investigate the effect of
proteasome inhibition on cardiomyocytes. We also used
tunicamycin, an inhibitor of N-linked glycosylation, as an ER
stress inducer without affecting proteasome activity.
2. Methods
2.1 Materials
MG132, epoxomicin, and tunicamycin were purchased from Sigma
Chemical Co. (St Louis, MO, USA). The antibodies for CHOP, XBP1,
ATF6, and actin were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The antibodies for phospho-JNK and JNK
were obtained from Cell Signaling Technology, Inc. (Danvers, MA,
USA). The antibodies for caspase-12 and HP1a were obtained
from Sigma Chemical Co., while those for Lys-Asp-Glu-Leu (KDEL)
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were
obtained from Assay Designs, Inc. (Ann Arbor, MI, USA) and Millipore
Co. (Billerica, MA, USA). Z-Ala-Thr-Ala-Asp (Z-ATAD) and SP600125
were purchased from BioVision Inc. (Mountain View, CA, USA) and
Calbiochem (San Diego, CA, USA), respectively.
2.2 Preparation of neonatal rat cardiomyocytes
Primary cardiomyocyte cultures were prepared from neonatal rat
hearts as described previously.
16 All procedures were in accordance
with the guiding principles of Osaka University School of Medicine,
Position of the American Heart Association on Research Animal
Use, and the Guide for the Care and Use of Laboratory Animals
published by the US National Institute of Health (NIH Publication
No. 85-23, revised 1996).
2.3 Proteasome activity assay
Chymotrypsin-like activities of proteasome were assayed using the
ﬂuorogenic peptides Suc-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin
(LLVY-AMC) (Biomol, Plymouth Meeting, PA, USA) according to the
method reported previously.
15 Brieﬂy, after the treatment with
MG132 or epoxomicin for 30 min, cultured rat neonatal cardiomyo-
cytes were harvested, lysed in proteasome buffer (10 mmol/L
Tris–HCl, pH 7.5, 1 mmol/L ethylene diamine tetraacetic acid
(EDTA), 2 mmol/L adenosine-5’-triphosphate, 20% glycerol, and
4 mmol/L dithiothreitol), and centrifuged at 13 000 g at 48C for
10 min. Then the supernatant (20 mg of protein) was incubated
with proteasome activity assay buffer (0.05 mol/L Tris–HCl, pH
8.0, 0.5 mmol/L EDTA, 40 mmol/L LLVY-AMC) for 1 h at 378C. The
reaction was stopped by adding 0.9 mL of cold water and placing
the reaction mixture on ice for at least 10 min. Subsequently,
the ﬂuorescence of the solution was measured by Fluorescence
Microplate Reader (Gemini XS; Molecular Devices, Sunnyvale, CA,
USA) with excitation at 380 nm (Ex) and emission at 440 nm (Em).
All readings were standardized relative to the ﬂuorescence intensity
of an equal volume of free 7-amino-4-methylcoumarin (Sigma)
solution (40 mmol/L).
2.4 Caspase-12 activity assay
Caspase-12 activity was assayed using its substrate ATAD-7-amino-4-
triﬂuoromethyl coumarin. Cell lysate aliquots were assayed by
Fluorescence Microplate Reader (Gemini XS; Molecular Devices)
with 400 nm excitation and 505 nm emission ﬁlter according to the
manufacturer’s protocol (BioVision).
2.5 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenol
tetrazolium bromide assay
Cardiomyocytes were seeded at 3   10
4/well in 96-well plates. After
MG132 administration at appropriate conditions, cell numbers were
measured with a water-soluble tetrazolium reagent [WST-8; 2-
(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-
2H-tetrazolium, monosodium salt] (Dojindo Laboratories, Kuma-
moto, Japan) according to the manufacturer’s instructions. Cell
viability was expressed as a percentage of the control. The wave-
lengths used in this assay were 450 nm (sample) and 630 nm
(reference).
2.6 Western blot analysis
Cardiomyocytes were lysed in the buffer (0.15 mmol/L, NaCl
0.05 mmol/LTris–HCl, pH 7.2, 1% Triton X-100, 1% sodium deoxycho-
late, 0.1% SDS) containing a protease inhibitor cocktail (Nakarai
Tesque, Kyoto, Japan). Electrophoresis, immunoblotting, and detec-
tion were done as described previously.
15
2.7 Reverse transcriptional polymerase chain
reaction
After rat cardiomyocytes were treated with the drugs for 6 h, XBP1
mRNA splicing was assessed using reverse transcriptional polymer-
ase chain reaction (PCR) method. The primers that spanned the
splice site are designed as followed: forward, ACGAGAGAAAACT-
CATGG; reverse, ACAGGGTCCAACTTGTCC (Figure 1D). This pair of
primers can detect both spliced and unspliced XBP1 at the size of
290 and 264 bp, respectively. The primers for GAPDH are forward,
CATCAACGACCCCTTCATTGACCTCAACTA;reverse,TCCACGATGCCAA
AGTTGTCATGGATGACC. PCR products were resolved on a 2%
agarose gel and viewed by UV illumination.
2.8 Real-time quantitative polymerase chain
reaction
We obtained samples after the drug treatment and then they were
prepared according to the Omniscript Reverse Transcription
Handbook (QIAGEN Inc., Hilden, Germany). The rat primers and
probes used for quantiﬁcation of glucose-regulated protein (GRP)
78, GRP94, CHOP, and GAPDH were all designed according to
the manufacturer’s protocol (Applied Biosystems, Foster City, CA,
USA. https://www.appliedbiosystems.com/). Real-time PCR was
performed with an ABI PRISM 7000 Sequence Detection System
ER chaperone attenuates cardiomyocyte death induced by proteasome inhibition 601
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 Figure 1 Effects of pharmacological proteasome inhibitors on the proteasome activity, cell death and endoplasmic reticulum stress-induced transcriptional
factors in cultured cardiomyocytes. (A) Proteasome activity after the treatment with MG132 (MG) (0.25, 0.5, 1.0 mmol/L), epoxomicin (Epo) (0.025, 0.05,
0.1 mmol/L) or tunicamycin (Tu) (1.0 mg/mL) for 30 min. Experiments were repeated independently for three times (n ¼ 3 in each experiment). (B) Cardiomyo-
cyte viability after the treatment with MG, Epo or Tu for 48 h. Experiments were repeated independently for four times (n ¼ 6 in each experiment). (C) Western
blot analysis of spliced and unspliced X-box binding protein 1 (XBP1) proteins after the treatment with MG (0.25, 0.5, 1.0 mmol/L), Epo (0.1 mmol/L) or Tu
(1.0 mg/mL) for 6 h. Actin and HP1a were used as the internal controls of cytosolic and nuclear fractions, respectively. (D) The upper panel shows the design
of polymerase chain reaction (PCR) primers for XBP1 messenger ribonucleic acid (mRNA) used in this study. This pair of primers can detect both unspliced
and spliced XBP1 mRNA. The middle and lower panels are representative and quantitative results of reverse transcriptional PCR for spliced and unspliced
XBP1 mRNA after the treatment with MG (0.25, 0.5, 1.0 mmol/L), Epo (0.1 mmol/L) or Tu (1.0 mg/mL) for 6 h. Glyceraldehyde-3-phosphate dehydrogenase
was used as the internal control of mRNA expression. (E) Western blot analysis of ATF6 (activating transcription factor 6) in cytosolic and nuclear fractions
after the treatment with MG (0.25, 0.5, 1.0 mmol/L), Epo (0.1 mmol/L) or Tu (1.0 mg/mL) for 6 h. The quantitative data in C, D, and E were achieved from
three independent experiments. (Asterisk) P , 0.05 vs. control.
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 (Applied Biosystems) by the relative standard curve method. The
thermal cycle reaction was performed as follows: 508C for 2 min,
958C for 10 min followed by 40 cycles at 958C for 15 s, 608C for
1 min. The target amount was determined from the relative
standard curves constructed with serial dilutions of the control
total cDNA.
2.9 Ribonucleic acid interference
We ordered four different short interfering ribonucleic acid (siRNA)
from B-Bridge International, Inc. (Mountain View, CA, USA) to knock
down CHOP mRNA (CHOP siRNA-1: 50-CGAAGAGGAAGAAUCAAA-30,
siRNA-2: 50-GGAAACAGCGACUGAAGGA-30, siRNA-3: 50-GGGACUGA
GGGUAGACCAA-30, siRNA-4: cocktail containing equal amounts of
the above three types of siRNA). Rat cardiomyocytes were isolated
and then incubated in Dulbecco’s modiﬁed Eagle’s medium (Invitro-
gen Co., Carlsbad, CA, USA). Opti-MEM (Invitrogen Co.), siRNA oligo-
nucleotides (CHOP siRNA 1–4) (60 nmol/L) and Optifect (Invitrogen
Co.) were added 4 h after cardiomyocyte isolation. As a negative
control, cells were transfected with siRNA against ﬁreﬂy luciferase
from Photinus pyralis (GL2 siRNA).
2.10 Flow cytometry
An Annexin V-ﬂuorescein isothiocyanate (FITC) Apoptosis Detection
Kit was purchased from Sigma. After the treatment of MG132, car-
diomyocytes were washed twice with PBS and resuspended in
binding buffer. FITC-Annexin V and propidium iodide were added
according to the manufacturer’s protocol. The mixture was incu-
bated for 10 min in dark at room temperature and then cellular ﬂu-
orescence was measured with a FACSscan ﬂow cytometry (Becton,
Dickinson and Company, Franklin Lakes, NJ, USA).
2.11 Adenovirus transduction
Recombinant adenovirus harbouring GRP78 gene was constructed as
described previously,
17 and adenovirus harbouring LacZ was used as
a control. Adenovirus was transfected 24 h after cardiomyocytes
were isolated or 20 h after siRNA against CHOP was added. And
the experiments were performed another 24 h after adenovirus
infection.
2.12 Confocal ﬂuorescence microscopy
Cardiomyocytes were observed by confocal microscopy (Radiance
2100 Laser Scanning System Bio-Rad, Hemei Hempstead, UK) and
saved by LaserSharp 2000 (Bio-Rad). Alexa568 (red) (Invitrogen
Co.) was scanned by helium/neon laser (wavelength 543 nm laser
line) with long path 590 ﬁlter (560–700 nm excitation). Alexa488
(green) was captured by Argon laser (wavelength 488 nm laser
line) with band path 500–550 IR ﬁlter (500–550 nm excitation).
DAPI (blue) for nuclei staining of all cells was obtained in range of
400–470 nm excitation.
Figure 2 Endoplasmic reticulum chaperon expression by proteasome inhibition in cultured cardiomyocytes. Real-time polymerase chain reaction analysis of
glucose-regulated protein (GRP) 78 (A) and GRP94 (B)( n ¼ 3 in each experiment) and western blot analysis of Lys-Asp-Glu-Leu (KDEL) proteins (C) (upper and
lower bands indicate GRP94 and GRP78, respectively) after the treatment with MG132 (MG) (0.25, 0.5, 1.0 mmol/L), epoxomicin (Epo) (0.1 mmol/L) or tunicamycin
(Tu) (1.0 mg/mL) for 6 h. The western blot analysis and real-time PCR experiment were repeated for three times independently. (Asterisk) P , 0.05 vs. control.
ER chaperone attenuates cardiomyocyte death induced by proteasome inhibition 603
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 2.13 Statistical analysis
Data are expressed as the mean+SEM. The results of cardiac pro-
teasome activity, caspase-12 activity, cell viability and quantitative
analysis of western blot analysis, real-time PCR, reverse
transcription-PCR, and ﬂow cytometry were compared by one-
way factorial ANOVA followed by Bonferroni’s correction. For all
analyses, P , 0.05 was accepted as statistically signiﬁcant.
Figure 3 Activation of endoplasmic reticulum-initiated apoptosis signalling by proteasome inhibition in cultured cardiomyocytes. Real-time polymerase chain
reaction (A)( n ¼ 3 in each experiment) and western blot (B) analysis of CHOP [cytosine-cytosine-adenine-adenine-thymine (CCAAT) enhancer-binding protein
(C/EBP) homologous protein] after the treatment with MG132 (MG) (0.25, 0.5, 1.0 mmol/L) or epoxomicin (Epo) (0.1 mmol/L) for 6 h. Western blot analysis of
phospho-c-Jun-N-terminal kinase (JNK) (C) and pro-caspase-12 (D) after the treatment with MG (0.25, 0.5, 1.0 mmol/L) or Epo (0.1 mmol/L) for 1 and 6 h,
respectively. (E) Caspase-12 activity after the treatment with MG (0.25, 0.5, 1.0 mmol/L) or Epo (0.1 mmol/L) for 6 h in cultured cardiomyocytes. Experiments
were repeated independently for three times (n ¼ 3 in each experiment). The quantitative data were achieved from three independent experiments. (Asterisk)
P , 0.05 vs. control.
H.Y. Fu et al. 604
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 Figure 4 Effects of blockade of endoplasmic reticulum (ER)-initiated apoptosis signalling on apoptosis by proteasome inhibition in cultured cardiomyocytes.
Effects of four different types of siRNA (short interfering ribonucleic acid) targeting CHOP [CCAAT enhancer-binding protein (C/EBP) homologous protein] on
CHOP mRNA (A)( n ¼ 3 in each experiment) and protein expression (B) after the treatment with MG132 (MG) (1.0 mmol/L) for 6 h. (C) Effects of SP600125 on
JNK (c-Jun-N-terminal kinase) phosphorylation after the treatment with MG (1.0 mmol/L) for 1 h. SP600125 was added 1 h before MG (1.0 mmol/L) adminis-
tration. (D) and (E) Effects of Z-Ala-Thr-Ala-Asp (Z-ATAD) on caspase-12 activation after the treatment with MG (1.0 mmol/L) for 6 h. Z-ATAD was added 1 h
before MG (1.0 mmol/L) administration (n ¼ 3 in each experiment). (F) Results of cardiomyocyte viability by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenol tet-
razolium bromide] assay after the co-treatment with MG (1.0 mmol/L) and blockers of ER-initiated apoptosis signals (n ¼ 6 in each experiment). Representative
(G) and quantitative (H) data of cardiomyocyte apoptosis by ﬂow cytometry (n ¼ 3 in each experiment). The population of cells in the lower right quadrant of dot
plot indicated apoptotic cardiomyocytes. Results of western blot and ﬂow cytometry analysis represented three independent experiments, while the result of
cell viability was from four independent experiments, respectively. (Asterisk) P , 0.05 vs. control; (Hash) P , 0.05 vs. MG (1.0 mmol/L).
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 3. Results
3.1 Proteasome activity and cell death by
proteasome inhibition in cultured cardiomyocytes
Pharmacological proteasome inhibitors such as MG132 or
epoxomicin dose-dependently decreased proteasome
activity and reduced cell viability in rat-cultured cardiomyo-
cytes. However, tunicamycin, an ER-stress inducer, induced
cardiomyocyte death without inhibiting proteasome activity
(Figure 1A and B).
3.2 Activation of endoplasmic reticulum stress-
induced transcriptional factors and endoplasmic
reticulum chaperone expression by proteasome
inhibition in cultured cardiomyocytes
After the addition of MG132 or epoxomicin, protein level of
unspliced XBP1 in cytosolic fraction, but not spliced XBP1 in
nuclear fraction, was increased in rat-cultured cardiomyo-
cytes (Figure 1C). The result of reverse transcriptional PCR
demonstrated that either MG132 or epoxomicin did not
change mRNA level of unspliced XBP1 in cardiomyocytes
(Figure 1D), suggesting that the increase in unspliced XBP1
protein level was due to the inhibition of its degradation
by proteasome inhibition. In contrast, pharmacological ER
stressor, tunicamycin, decreased unspliced XBP1 mRNA
expression and increased both mRNA and protein levels of
spliced XBP1 (Figure 1C and D). Proteasome inhibitors
increased the protein level of ATF6 in the nuclear fraction
in cultured cardiomyocytes (Figure 1E) to the similar
extent as tunicamycin did. Importantly, proteasome inhi-
bition did not induce the mRNA and protein expressions of
either GRP78 or GRP94, although tunicamycin increased
both of them (Figure 2A–C).
3.3 Activation of endoplasmic reticulum-initiated
apoptosis signalling and cell death by proteasome
inhibition in cultured cardiomyocytes
Proteasome inhibition by MG132 or epoxomicin increased
both mRNA and protein levels of CHOP in rat-cultured cardi-
omyocytes (Figure 3A and B). In addition, it also induced JNK
phosphorylation (Figure 3C) and caspase-12 activation
(Figure 3D and E). CHOP siRNA 1 or 4, but not 2 or 3, signiﬁ-
cantly attenuated the MG132-induced increase in both
mRNA and protein levels (Figure 4A and B). SP600125, an
inhibitor of JNK phosphorylation, prevented the JNK phos-
phorylation by MG132 at both 5 and 10 mmol/L
(Figure 4C). Z-ATAD, a caspase-12 inhibitor, attenuated the
activation of caspase-12 by MG132 at 10, but not 2, mmol/
L( Figure 4D and E). Cell viability analysed by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenol tetrazolium bromide
(MTT) assay showed that siRNA targeting CHOP, but not
SP600125 (5 mmol/L) or Z-ATAD (10 mmol/L) compound,
prevented cell death induced by proteasome inhibition in
rat-cultured cardiomyocytes (Figure 4F). Furthermore, con-
sistent with the data of MTT assay, ﬂow cytometry analysis
showed that siRNA targeting CHOP, but not SP600125 or
Z-ATAD, attenuated the apoptosis of cardiomyocyte
induced by proteasome inhibition (Figure 4G and H).
3.4 Overexpression of glucose-regulated protein 78
attenuated endoplasmic reticulum stress and cell
death by proteasome inhibition in cultured
cardiomyocytes
Location of GRP78 overexpressed by adenovirus in cultured
cardiomyocyte was almost consistent with that of protein
disulphide isomerase, an ER-resident oxidoreductase
(Figure 5A). The increase in GRP78 expression was conﬁrmed
by western blot analysis with the speciﬁc antibody of KDEL.
Interestingly, GRP78 overexpression speciﬁcally inhibited
the induction of CHOP, but not activation of caspase-12 or
JNK (Figure 5B–F). Moreover, GRP78 overexpression dose-
dependently decreased CHOP induction and increased cardi-
omyocyte viability (Figure 5G–J). Furthermore, the ﬂow
cytometry analysis also showed that overexpression of
GRP78 attenuated apoptosis induced by proteasome inhi-
bition in rat-cultured cardiomyocytes (Figure 5K and L).
The overexpression of GRP78 combined with CHOP knock-
down did not show additional effects on cardiomyocytes via-
bility compared with GRP78 overexpression or CHOP
knockdown alone (Figure 5M).
4. Discussion
The present study demonstrated that proteasome inhibitors,
such as MG132 and epoxomicin, activated the ER
stress-induced transcriptional factor ATF6, but not XBP1,
without commeasurable expression of ER chaperone upon
proteasome inhibition. Furthermore, proteasome inhibition
induced cardiac apoptosis via CHOP-, but not JNK- or
Figure 4 Continued.
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 Figure 5 Overexpression of glucose-regulated protein (GRP) 78 reduced cardiomyocyte death by proteasome inhibition. (A) GRP78 was overexpressed by ade-
novirus at multiplicity of infection (MOI) 30 in cultured cardiomyocyte. Confocal ﬂuorescence microscopy revealed that KDEL, PDI (protein disulphide isomerase)
and DAPI were stained green, red and blue, respectively. (B) GRP78 expression, CCAATenhancer-binding protein (C/EBP) homologous protein (CHOP) expression
and activation of capase-12 were investigated after the treatment with MG132 (MG) (1.0 mmol/L) for 6 h at appropriate concentrations, while
phospho-c-Jun-N-terminal kinase (JNK) was detected 1 h after MG administration. (C–F) Quantitative data of GRP78 expression (C), CHOP expression (D),
casapase-12 activation (E) and JNK phosphorylation (F). (G–I) Representative (G) and quantitative (H, I) data for the expressions of endoplasmic reticulum cha-
perone (KDEL) and CHOP protein after GRP78 was overexpressed in a dose-dependent manner. MG (1.0 mmol/L) was administrated for 6 h. (J–L) Effects of over-
expression of GRP78 on cardiomyocyte viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenol tetrazolium bromide (MTT) analysis (J)( n ¼ 6 in each experiment)
and cardiomyocytes apoptosis by ﬂow cytometry (K, L)( n ¼ 3 in each experiment) after MG (1.0 mmol/L) administration. (M) Effects of GRP78 overexpression
combined with CHOP knockdown on cardiomyocyte viability by MTTanalysis after proteasome inhibition (n ¼ 5 in each group). Results of western blot and ﬂow
cytometry analysis represented three independent experiments, while the result of cell viability was from four independent experiments, respectively. (Asterisk)
P , 0.05 vs. control; (Hash) P , 0.05 vs. MG (1.0 mmol/L).
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 caspase-12-, dependent pathway. Adenovirus-mediated
GRP78 overexpression attenuated CHOP expression and
rescued cardiomyocyte death by proteasome inhibition.
These results suggest that proteasome inhibition caused ER
stress without a compensatory increase in ER chaperones
and induced cardiac apoptosis via the CHOP-dependent
pathway. Supplement and/or pharmacological induction of
GRP78 may be a potential therapeutic tool to attenuate
cardiac damage by proteasome inhibition.
After proteasome inhibition, cleaved ATF6 protein in the
nuclear fraction was increased, which might be due to the
decrease in ATF6 degradation by proteasome inhibition
and/or increase in the ATF6 cleavage.
18 However, consist-
ent with the previous report,
19 we could not detect the
increase of spliced XBP1 at either mRNA or protein level,
suggesting that XBP1 was not activated by proteasome inhi-
bition. Since overexpression of cleaved ATF6 could
up-regulate ER chaperone expression,
20,21 ER chaperone
should be induced due to the increase in cleaved ATF6 by
proteasome inhibition. In our study, however, ER chaperons
were not up-regulated after proteasome inhibition,
suggesting there are some mechanisms that may prevent
up-regulation of ER chaperone by cleaved ATF6. Since
unspliced XBP1 protein acts as a dominant negative inhibi-
tor of the spliced form and deactivates ATF6 by hetero-
dimerization,
19,22–24 one possible mechanism is that
increased protein levels of unspliced XBP1 probably due
to the decelerated degradation by proteasome inhibition
Figure 5 Continued.
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 may prevent the induction of ER chaperone. No compensa-
tory increase in the ER chaperone may deteriorate the ER
function to cope with ER stress when proteasome activity
is inhibited (Figure 6).
In the present study, proteasome inhibition activated
ER-initiated apoptotic signalling such as CHOP, caspase-12,
and JNK. Using siRNA targeting CHOP and pharmacological
inhibitors for caspase-12 and JNK, we found that CHOP
knockdown partially, but signiﬁcantly, inhibited cardiac
apoptosis, while other pharmacological inhibitors did not.
These ﬁndings suggest that CHOP, but not caspase-12 or
JNK, mainly mediated cardiac apoptosis by proteasome inhi-
bition. Recent research showed that the importance of three
ER-initiated apoptotic signals is not equivalently involved in
the pathophysiology in ER stress-related diseases.
25–27
Importantly, CHOP knockdown only partially prevented car-
diomyocyte death by proteasome inhibition, suggesting that
other mechanisms to induce cell death would be involved.
Indeed, we have previously demonstrated that proteasome
deactivation increased pro-apoptotic regulatory protein
levels, such as p53 and Bax, and their knockdown also par-
tially, but signiﬁcantly, attenuated cardiac apoptosis.
15
These ﬁndings suggest that proteasome inhibition may
cause cardiac apoptosis via the ER stress-dependent and
-independent pathways.
We found overexpression of GRP78 could attenuate both
CHOP expression and cell death by proteasome inhibition
in cultured cardiomyocytes. In addition, the combination
of GRP78 overexpression and CHOP knockdown did not
show additional effects on preventing cardiomyocyte
death, indicating that cell survival by GRP78 overexpression
is predominantly through CHOP-dependent pathway. Further
investigation is needed to elucidated why GRP78 speciﬁcally
blocked CHOP induction among ER-initiated apoptotic
signals. In the present study, although CHOP knockdown or
GRP78 overexpression showed the small improvement of
cell survival when cardiomyocytes were treated with pro-
teasome inhibitors, these ﬁndings have some clinical rel-
evance. Since patients will repeatedly receive the
proteasome inhibitor for much longer time in the clinical
settings, even a small size of improvement will exert the
beneﬁcial effects on the patients who need to receive the
proteasome inhibitors.
We have previously demonstrated that both CHOP and
GRP78 expression were induced in samples from human
failing hearts and mouse failing hearts due to the pressure
overload.
28 These ﬁndings suggest that ER stress may be
involved in the pathogenesis in developing heart failure.
Although we did not have the opportunity to check the
ER-stress related signalling in the animal or human model
when proteasome is inhibited, our in vitro data strongly
suggest that proteasome inhibition may play an important
role in the cardiomyocyte death via the ER stress-dependent
pathways. The difference in the activation of ER stress-
related signalling may be dependent on the pathophysiology
of heart failure, and it is necessary to clarify how ER stress is
involved in pathogenesis of cardiac diseases.
The ubiquitin-proteasome system is impaired in pathologi-
cal cardiovascular conditions, such as ischaemia/reperfusion
andfailingheartsresultingfrompressureoverload.
15,29Here,
we found that proteasome inhibition induced ER-initiated
apoptosis in cultured cardiomyocytes, supporting the idea
that the impairment of the ubiquitin-proteasome system
may play a crucial role in the development of heart disease.
Bortezomib(PS-341)isclinicallyusedasanovelclassofantic-
ancer agents against haematological malignancy and solid
Figure 6 Schematic diagram of endoplasmic reticulum (ER)-chaperone glucose-regulated protein (GRP) 78 attenuating cardiomyocyte death by proteasome
inhibition. Proteasome inhibition induces ER stress with the activation of activating transcription factor 6 (ATF6), but not X-box binding protein 1 (XBP1), in car-
diomyocytes. Furthermore, proteasome inhibition activates ER-initiated apoptosis signalling such as CCAATenhancer-binding protein (C/EBP) homologous protein
(CHOP), JNK (c-Jun-N-terminal kinase) and caspase-12. Importantly, the expression of GRP78 was not enhanced probably due to the increased protein level of
unspliced XBP1, which may further deteriorate ER stress. Overexpression of GRP78 attenuated cardiomyocyte death by proteasome inhibition via CHOP-
dependent pathway. U-XBP1, S-XBP1, and C-ATF6 indicate unspliced XBP1, spliced XBP1, and cleaved ATF6, respectively.
ER chaperone attenuates cardiomyocyte death induced by proteasome inhibition 609
b
y
 
g
u
e
s
t
 
o
n
 
O
c
t
o
b
e
r
 
3
1
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 tumour. Although bortezomib is not available currently in our
hands, MG132 or epoxomicin used in the present study has
similar characteristics as bortezomib to cause cell death via
ER stress-related signalling.
30,31 Recently, some studies
reported that the treatment with bortezomib was associated
with cardiac dysfunction.
13,14 In addition, imatinib mesylate,
atyrosinekinaseinhibitorusedasananticancerdrug,wasalso
reported to cause ER stress and heart failure.
32 Therefore,
based on these ﬁndings, we need to monitor cardiac function
carefullywhileusinganticancerdrugsthatpotentiallydisrupt
protein quality control.
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